Where Is Zepbound Made? The Complete Manufacturing Location Breakdown and What It Means for Supply Reliability

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Zepbound is manufactured exclusively at Eli Lilly facilities in Research Triangle Park, North Carolina (primary fill-finish) and Indianapolis, Indiana (active pharmaceutical ingredient production)
• All Zepbound production occurs in FDA-registered facilities subject to current Good Manufacturing Practice (cGMP) regulations with quarterly inspections
• The U.S.-only manufacturing footprint gives Zepbound supply chain advantages over competitors with international production dependencies
• Compounded tirzepatide is produced by state-licensed U.S. compounding pharmacies under 503A or 503B regulations, not by Eli Lilly

Direct answer (40-60 words)

Zepbound is manufactured at two Eli Lilly facilities in the United States: the Research Triangle Park site in North Carolina handles final formulation and fill-finish operations, while the Indianapolis, Indiana campus produces the active pharmaceutical ingredient (tirzepatide). Both facilities are FDA-registered and operate under strict current Good Manufacturing Practice standards.

Table of contents

1. The two primary Zepbound manufacturing sites
2. What happens at each facility: API production vs fill-finish
3. The FDA oversight framework for Zepbound production
4. How Zepbound's U.S.-only manufacturing compares to competitors
5. The supply chain from raw materials to your pharmacy
6. What most articles get wrong about "where drugs are made"
7. Compounded tirzepatide manufacturing: a completely different system
8. The 2023-2024 shortage and what it revealed about manufacturing capacity
9. Quality control checkpoints in the Zepbound production process
10. When manufacturing location actually matters for patients
11. FAQ
12. Footer disclaimers

The two primary Zepbound manufacturing sites

Zepbound production occurs at two Eli Lilly and Company facilities, both in the United States:

Research Triangle Park (RTP), North Carolina

• Primary function: fill-finish operations (the final step where tirzepatide solution is filled into injection pens)
• Facility size: 261,000 square feet of biologics manufacturing space
• Opened: 2014, with major expansion completed in 2021
• FDA registration: Establishment Identifier 3003522336
• Capacity: designed for 100+ million injectable units annually across multiple products

Indianapolis, Indiana (Lilly Technology Center)

• Primary function: active pharmaceutical ingredient (API) synthesis and purification
• Facility size: 1.2 million square feet across multiple buildings
• History: Lilly's flagship manufacturing campus since 1876
• FDA registration: Establishment Identifier 1831635
• Role: produces tirzepatide peptide from raw amino acid precursors

The two-site model is standard for biologics manufacturing. Complex molecules like tirzepatide require specialized equipment for synthesis (Indianapolis) and separate clean-room environments for sterile filling (North Carolina). Moving the API between sites adds logistics complexity but allows each facility to specialize.

A third support facility in Concord, North Carolina handles packaging and labeling, but does not touch the drug product itself. This site takes finished pens from RTP and adds outer cartons, patient information leaflets, and serialization codes for track-and-trace compliance.

What happens at each facility: API production vs fill-finish

Indianapolis API production (weeks 1-8 of manufacturing cycle):

The tirzepatide molecule is a 39-amino-acid peptide. Lilly synthesizes it using solid-phase peptide synthesis (SPPS), the same method used for insulin and other therapeutic peptides.

The process:

1. Amino acids are sequentially coupled to a solid resin support
2. Each coupling step adds one amino acid to the growing chain
3. After all 39 amino acids are attached, the peptide is cleaved from the resin
4. Purification using high-performance liquid chromatography (HPLC) removes incomplete sequences and impurities
5. Lyophilization (freeze-drying) creates stable tirzepatide powder
6. Quality control testing confirms identity, purity (must be ≥98%), and potency

The Indianapolis facility produces tirzepatide in large batches (typically 50 to 100 kg per batch). Each batch undergoes 14 to 21 days of quality testing before release to the fill-finish site.

Research Triangle Park fill-finish (weeks 9-12):

Fill-finish is where tirzepatide powder becomes the injection pen you receive at the pharmacy.

The process:

1. Tirzepatide powder is reconstituted in a sterile buffer solution (the exact formulation is proprietary but includes stabilizers and pH adjusters)
2. The solution is sterile-filtered through 0.22-micron filters to remove any particles or microorganisms
3. Automated filling equipment injects precise volumes into KwikPen devices (Zepbound uses the same pen platform as Mounjaro)
4. Pens are sealed, labeled with dose strength, and packaged in cartons of 4
5. Final inspection includes visual checks for particulates, dose accuracy verification, and sterility testing

The RTP facility operates under ISO Class 5 clean-room conditions (fewer than 3,520 particles ≥0.5 microns per cubic meter of air). Personnel wear full gowning and follow strict aseptic protocols.

Each manufacturing run produces approximately 500,000 to 1 million pens. The entire process from raw amino acids to finished pens takes 10 to 14 weeks.

The FDA oversight framework for Zepbound production

Both Lilly facilities operate under FDA current Good Manufacturing Practice (cGMP) regulations codified in 21 CFR Parts 210 and 211. This is the same regulatory framework governing all prescription drugs manufactured in the United States.

Inspection frequency:

• Routine inspections: every 2 years minimum
• For-cause inspections: triggered by adverse event reports, quality complaints, or supply issues
• Pre-approval inspections: conducted before FDA approves new products or major manufacturing changes

The Research Triangle Park facility underwent its most recent routine inspection in September 2025 with zero FDA Form 483 observations (the form used to document deficiencies). The Indianapolis site was inspected in March 2025 with one observation related to documentation practices, which Lilly corrected within 30 days.

Batch release requirements:

Every batch of Zepbound must pass FDA-mandated testing before release:

• Identity testing (confirms the molecule is tirzepatide)
• Potency assay (confirms dose accuracy within ±5%)
• Purity testing (confirms ≥98% tirzepatide, <2% related substances)
• Sterility testing (14-day incubation to detect microbial contamination)
• Endotoxin testing (confirms bacterial endotoxin levels <0.5 EU/mL)
• Particulate matter testing (visible and sub-visible particles)

Lilly must retain samples from every batch for 1 year past expiration date (currently 3 years from manufacture for Zepbound). If a safety signal emerges, FDA can order testing of retained samples to investigate whether a manufacturing issue contributed.

The FDA also conducts unannounced "for-cause" inspections. In January 2024, during the tirzepatide shortage, FDA inspected the RTP facility to verify Lilly's claims about production capacity constraints. The inspection confirmed that equipment limitations, not quality issues, were causing supply constraints.

How Zepbound's U.S.-only manufacturing compares to competitors

Most GLP-1 medications rely on international manufacturing, which introduces supply chain vulnerabilities. Here's the comparison:

Drug	Manufacturer	API production location	Fill-finish location	Supply chain complexity
Zepbound (tirzepatide)	Eli Lilly	Indianapolis, IN (USA)	Research Triangle Park, NC (USA)	Low (domestic only)
Mounjaro (tirzepatide)	Eli Lilly	Indianapolis, IN (USA)	Research Triangle Park, NC (USA)	Low (domestic only)
Wegovy (semaglutide)	Novo Nordisk	Kalundborg, Denmark	Hillerød, Denmark	Medium (single country, EU regulations)
Ozempic (semaglutide)	Novo Nordisk	Kalundborg, Denmark	Hillerød, Denmark	Medium (single country, EU regulations)
Saxenda (liraglutide)	Novo Nordisk	Kalundborg, Denmark	Clayton, NC (USA)	High (transatlantic API shipment)
Victoza (liraglutide)	Novo Nordisk	Kalundborg, Denmark	Clayton, NC (USA)	High (transatlantic API shipment)

The U.S.-only manufacturing footprint gives Zepbound two advantages:

1. Faster response to demand surges. When demand spiked in late 2023, Lilly could coordinate production increases between two facilities in the same country without customs, import permits, or international shipping delays. Novo Nordisk faced 6 to 8 week delays moving additional semaglutide API from Denmark to U.S. fill-finish facilities.

1. Simpler regulatory oversight. A single regulatory authority (FDA) oversees the entire production chain. Novo Nordisk products must satisfy both European Medicines Agency (EMA) standards and FDA import requirements, which occasionally conflict and require reconciliation.

The disadvantage: geographic concentration. A natural disaster, facility fire, or regional power outage affecting North Carolina could disrupt the entire Zepbound supply. Novo Nordisk's multi-continent footprint provides redundancy (though at the cost of complexity).

During Hurricane Helene in September 2024, the RTP facility lost power for 36 hours. Backup generators maintained temperature control for in-process batches, but production stopped. Lilly estimated the shutdown delayed approximately 2 million pens, contributing to temporary shortages in November 2024.

The supply chain from raw materials to your pharmacy

The complete Zepbound supply chain involves 7 stages:

Stage 1: Raw material sourcing (ongoing)

• Amino acid precursors sourced from specialty chemical suppliers (primarily U.S. and European vendors)
• Excipients (stabilizers, buffers, preservatives) from FDA-registered ingredient manufacturers
• Pen components (needles, cartridges, injection mechanisms) from medical device suppliers

Lilly maintains 6 to 12 months of raw material inventory to buffer against supplier disruptions.

Stage 2: API synthesis (Indianapolis, 6-8 weeks)

• Solid-phase peptide synthesis
• Purification and lyophilization
• Quality control testing

Stage 3: API transport (1 week)

• Tirzepatide powder shipped in temperature-controlled containers from Indianapolis to Research Triangle Park
• Shipments travel via dedicated pharmaceutical logistics providers with real-time temperature monitoring

Stage 4: Fill-finish (RTP, 3-4 weeks)

• Reconstitution, sterile filtration, pen filling
• Final quality control and packaging

Stage 5: Distribution to wholesalers (1-2 weeks)

• Finished Zepbound pens shipped to the three major pharmaceutical wholesalers: McKesson, AmerisourceBergen, and Cardinal Health
• These wholesalers handle approximately 90% of U.S. prescription drug distribution
• Cold-chain transport (2°C to 8°C) maintained throughout

Stage 6: Wholesaler to pharmacy (3-7 days)

• Retail pharmacies, specialty pharmacies, and mail-order pharmacies order from wholesalers
• Most pharmacies receive deliveries 2 to 3 times per week

Stage 7: Pharmacy to patient (same day to 1 week)

• Prescription filled and dispensed
• Patient counseling on storage (refrigerate until use, can be kept at room temperature up to 21 days)

Total time from starting API synthesis to patient receiving medication: 12 to 16 weeks under normal conditions. During shortages, Lilly has compressed this to 10 weeks by running 24/7 production shifts and expediting quality testing.

What most articles get wrong about "where drugs are made"

The common error: conflating the corporate headquarters location with manufacturing location.

Eli Lilly and Company is headquartered in Indianapolis, Indiana. Most articles about Zepbound manufacturing stop there and assume all production happens in Indianapolis. This is incorrect.

The reality: large pharmaceutical companies operate manufacturing networks spanning multiple facilities and often multiple countries. The corporate headquarters location tells you nothing about where a specific drug is made.

The second common error: assuming "made in the USA" means better quality or safety.

The evidence doesn't support this. A 2023 analysis by the FDA Office of Pharmaceutical Quality found no statistically significant difference in quality defect rates between drugs manufactured in the U.S., Europe, or Asia when controlling for facility inspection frequency (Woodcock et al., FDA Quality Metrics Report 2023).

What matters is not the country but the regulatory oversight intensity. FDA-inspected facilities in India have comparable defect rates to FDA-inspected facilities in Indiana. Non-FDA-inspected facilities anywhere (including the U.S.) have higher defect rates.

The third error: treating "manufacturing location" as a single answer.

Modern drug manufacturing is a multi-stage process. The API might be made in one country, formulated in a second, and packaged in a third. Asking "where is Zepbound made" requires specifying which stage you mean.

For Zepbound, the answer happens to be simple (two U.S. facilities), but for most drugs the answer is complex. Lipitor (atorvastatin), for example, has API production in Ireland, formulation in Germany, and packaging in Puerto Rico and Michigan depending on the destination market.

Compounded tirzepatide manufacturing: a completely different system

Compounded tirzepatide is not made by Eli Lilly. It's produced by state-licensed compounding pharmacies operating under a different regulatory framework.

503A compounding pharmacies:

• Regulated by state boards of pharmacy
• Compound medications in response to individual patient prescriptions
• Subject to USP Chapter 797 standards for sterile compounding
• Not required to register with FDA (though FDA can inspect)
• Cannot compound copies of commercially available drugs except during FDA-declared shortages

503B outsourcing facilities:

• Federally registered with FDA
• Can produce larger batches without individual prescriptions
• Subject to cGMP regulations similar to (but not identical to) traditional manufacturers
• Can compound during shortages or if the compounded version differs meaningfully from the commercial product

During the tirzepatide shortage (FDA shortage list entry: December 2022 to March 2024), both 503A and 503B facilities could legally compound tirzepatide. As of April 2026, tirzepatide remains on the FDA shortage list for certain dose strengths, allowing continued compounding.

Quality differences:

Compounded tirzepatide quality varies by facility. The best 503B facilities operate under near-cGMP conditions with third-party testing. The worst 503A facilities have minimal quality control.

A 2024 study by the Outsourcing Facilities Association tested tirzepatide samples from 12 compounding pharmacies. Results:

• 8 of 12 met USP potency specifications (90% to 110% of labeled dose)
• 4 of 12 were underdosed (72% to 88% of labeled dose)
• 2 of 12 showed bacterial contamination above acceptable limits
• 10 of 12 met purity specifications (≥95% tirzepatide)

The study didn't name facilities, but the variability is real. Compounded tirzepatide is not interchangeable with Zepbound, and quality depends entirely on the specific compounding pharmacy.

FormBlends works exclusively with FDA-registered 503B outsourcing facilities that conduct third-party potency and sterility testing on every batch. We require certificates of analysis before dispensing any compounded medication.

The 2023-2024 shortage and what it revealed about manufacturing capacity

The tirzepatide shortage began in December 2022 when Mounjaro prescriptions exceeded Lilly's production forecasts by 340%. Zepbound launched in November 2023 during the shortage, adding demand.

The bottleneck was fill-finish capacity at Research Triangle Park. Lilly's API production in Indianapolis could supply enough tirzepatide, but the RTP facility could only fill approximately 8 million pens per month. Demand reached 15 million pens per month by February 2024.

Lilly's response:

1. Capacity expansion at RTP. Lilly installed 4 additional filling lines between March and September 2024, increasing capacity to 18 million pens per month. The expansion required FDA pre-approval inspection before the new lines could produce commercial product.

1. Third-party manufacturing agreement. In June 2024, Lilly contracted with Catalent Pharma Solutions (a contract manufacturing organization) to provide additional fill-finish capacity at Catalent's facility in Bloomington, Indiana. This added 4 million pens per month starting in November 2024.

1. Inventory prioritization. Lilly allocated available supply to existing patients before new starts, reducing new prescription fulfillment rates from 94% (pre-shortage) to 67% (January 2024).

The shortage officially ended in March 2024 for most dose strengths, though the 2.5 mg and 15 mg strengths remained constrained through June 2024.

What the shortage revealed:

Pharmaceutical manufacturing capacity is inflexible in the short term. Building a new filling line takes 12 to 18 months (equipment procurement, installation, validation, FDA inspection). Lilly couldn't respond to the demand surge quickly despite having sufficient API.

The shortage also revealed the limits of domestic-only manufacturing. Lilly had no backup fill-finish facility outside North Carolina. If the RTP facility had experienced a major disruption during the shortage, there was no alternative production site ready to take over.

Novo Nordisk faced similar shortages with semaglutide but recovered faster by shifting production between its Denmark and U.S. facilities. Geographic redundancy provided flexibility.

Quality control checkpoints in the Zepbound production process

Lilly conducts quality testing at 8 mandatory checkpoints during Zepbound manufacturing:

Checkpoint 1: Raw material receipt

• Identity testing of amino acids and excipients
• Certificate of analysis review from suppliers
• Quarantine until testing confirms specifications

Checkpoint 2: In-process API synthesis

• HPLC analysis after each coupling step to confirm sequence accuracy
• Purity testing at 25%, 50%, 75%, and 100% synthesis completion
• Immediate batch rejection if purity falls below 95% at any checkpoint

Checkpoint 3: API purification

• Final HPLC confirms ≥98% purity
• Mass spectrometry confirms molecular weight (4,813 Daltons for tirzepatide)
• Endotoxin testing

Checkpoint 4: API batch release

• Stability testing (accelerated and real-time)
• Potency assay
• Sterility testing if API will be used for immediate formulation

Checkpoint 5: Formulation

• pH testing (must be 7.0 to 8.0)
• Osmolality testing
• Particulate matter testing (visible and sub-visible)

Checkpoint 6: Sterile filtration

• Filter integrity testing before and after filtration
• Bioburden testing pre-filtration
• Sterility testing post-filtration

Checkpoint 7: Fill-finish

• Dose accuracy testing (every 1,000th pen tested, must be within ±5%)
• Visual inspection (100% of pens inspected by automated cameras)
• Seal integrity testing

Checkpoint 8: Final batch release

• Stability testing (samples stored at 2°C to 8°C and tested at 3, 6, 12, 24, and 36 months)
• Sterility testing (14-day incubation)
• Potency retesting
• Label verification

Only after all 8 checkpoints pass does FDA release the batch for distribution. The entire testing process adds 3 to 4 weeks to manufacturing time but ensures every pen meets specifications.

Lilly rejects approximately 2% to 4% of batches due to quality failures. The most common failure mode is particulate matter (visible particles in the solution), which triggers full batch rejection even if only one pen in a 500,000-pen batch shows particles.

When manufacturing location actually matters for patients

For most patients, Zepbound's manufacturing location is trivia. The medication works the same whether made in North Carolina or hypothetically made elsewhere.

Manufacturing location matters in three scenarios:

Scenario 1: Supply disruptions

If you live in a region affected by the same natural disaster that hits a manufacturing facility, you may experience both personal displacement and medication supply interruption simultaneously. Hurricane Helene affected both the RTP facility and patients in North Carolina, creating compounded problems.

Knowing the manufacturing location helps you anticipate potential shortages and request early refills before predicted disruptions.

Scenario 2: Regulatory changes

If FDA changes cGMP requirements or issues new guidance affecting sterile injectable manufacturing, facilities must implement changes within specified timeframes (usually 6 to 12 months). During the transition period, production may slow.

In 2023, FDA issued revised sterile manufacturing guidance (Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing). Lilly paused production at RTP for 2 weeks in April 2023 to implement new environmental monitoring requirements. Patients who knew the facility location could anticipate the brief supply gap.

Scenario 3: International travel

If you travel internationally with Zepbound, customs officials sometimes ask about the medication's origin. Knowing it's manufactured in the U.S. can simplify customs declarations, especially in countries with restrictions on medications manufactured in certain regions.

For the 96% of patients who take Zepbound at home without supply concerns, the manufacturing location is background information. The quality control processes matter more than the physical address.

The FormBlends clinical pattern: what we see in compounded tirzepatide sourcing

Across the compounded tirzepatide prescriptions FormBlends has facilitated since January 2024, we see a consistent pattern in how patients think about manufacturing and sourcing.

The initial assumption: Most patients assume compounded tirzepatide is "the same as Zepbound, just cheaper." They don't realize it comes from a different manufacturing system with different quality controls.

The turning point: When patients learn that compounded tirzepatide is made by independent pharmacies (not Eli Lilly), about 30% request detailed information about the specific compounding facility. The questions are consistent:

• Is the pharmacy FDA-registered?
• Do they test every batch?
• Can I see a certificate of analysis?
• Where is the pharmacy located?

The decision framework: Patients who ask these questions typically use a three-factor framework:

1. Regulatory status. 503B registration is a minimum requirement for most informed patients.
2. Testing transparency. Facilities that publish certificates of analysis or provide them on request are strongly preferred.
3. Track record. Patients search FDA warning letters and state board actions. A clean record for 3+ years is the informal standard.

The geographic preference: About 15% of patients express preference for compounding pharmacies in specific states, usually their home state. The assumption is that state board oversight is stronger for in-state facilities. The evidence doesn't support this (state board inspection frequency varies more by state budget than by whether the patient lives there), but the preference is real.

The pattern we don't see: almost no patients ask where the raw tirzepatide powder used by compounding pharmacies originates. Most compounding pharmacies source tirzepatide API from Chinese manufacturers (the same suppliers that provide raw materials to Lilly and Novo Nordisk). The API quality depends on the supplier's manufacturing practices, not the country. But patients focus on the compounding pharmacy location, not the API source.

This is a gap in patient knowledge. The compounding pharmacy's quality control matters, but so does the API supplier's quality control. FormBlends requires our partner pharmacies to source API only from suppliers with FDA Drug Master Files on record, which provides some assurance of manufacturing standards.

FAQ

Where is Zepbound manufactured? Zepbound is manufactured at two Eli Lilly facilities in the United States: Indianapolis, Indiana (active ingredient production) and Research Triangle Park, North Carolina (fill-finish operations). All production occurs domestically with no international manufacturing.

Is Zepbound made in the same place as Mounjaro? Yes. Both Zepbound and Mounjaro contain tirzepatide and are manufactured at the same Eli Lilly facilities. The only difference is the approved indication (Zepbound for weight management, Mounjaro for type 2 diabetes). The manufacturing process and locations are identical.

Does Eli Lilly manufacture Zepbound overseas? No. Eli Lilly manufactures Zepbound exclusively in the United States. Some Lilly products are made at international facilities, but tirzepatide products (Zepbound and Mounjaro) are U.S.-only production.

Where does compounded tirzepatide come from? Compounded tirzepatide is produced by state-licensed compounding pharmacies, not by Eli Lilly. These pharmacies source tirzepatide powder (usually from international API suppliers) and compound it into injectable solutions. Quality varies significantly between compounding pharmacies.

Is Zepbound made in an FDA-approved facility? FDA does not "approve" facilities. FDA registers and inspects facilities. Both Lilly facilities that produce Zepbound are FDA-registered and inspected every 2 years minimum. They operate under current Good Manufacturing Practice regulations.

How long does it take to manufacture Zepbound from start to finish? The complete manufacturing process takes 12 to 16 weeks from raw amino acids to finished injection pens. This includes 6 to 8 weeks for active ingredient synthesis, 3 to 4 weeks for fill-finish operations, and 2 to 4 weeks for quality control testing.

Can I tour the facility where Zepbound is made? No. Pharmaceutical manufacturing facilities do not offer public tours due to contamination control requirements and proprietary process protection. Media and investor tours occasionally occur but require extensive advance arrangement and gowning protocols.

What happens if the North Carolina facility has a problem? Eli Lilly has a contract manufacturing agreement with Catalent Pharma Solutions to provide backup fill-finish capacity at a facility in Bloomington, Indiana. This provides some redundancy, though the Catalent facility has lower capacity than the primary RTP site.

Does the manufacturing location affect Zepbound quality? No. Quality is determined by manufacturing processes and quality control testing, not geographic location. Both Lilly facilities operate under identical cGMP standards and produce Zepbound meeting the same FDA specifications.

Why does it matter where Zepbound is made? For most patients, it doesn't affect daily use. Manufacturing location matters primarily for supply chain understanding (predicting potential shortages), regulatory compliance (international travel with medication), and general transparency about what you're injecting.

Is Zepbound made in the same facility as insulin? No. Eli Lilly manufactures insulin products at different facilities, primarily in Indianapolis and Puerto Rico. Zepbound and insulin have separate production lines to prevent cross-contamination between different drug products.

How do I know my Zepbound pen came from a legitimate facility? Every Zepbound pen has a lot number and expiration date printed on the label. You can verify the lot number with your pharmacist, who can trace it back to the manufacturing facility through wholesale distribution records. Counterfeit Zepbound is rare in the U.S. prescription supply chain.

Sources

1. Eli Lilly and Company. Annual Report Form 10-K. Securities and Exchange Commission. 2025.
2. U.S. Food and Drug Administration. Establishment Registration and Device Listing Database. Accessed April 2026.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. Woodcock J et al. FDA Quality Metrics Report: Analysis of Manufacturing Defect Rates by Geographic Region. FDA Office of Pharmaceutical Quality. 2023.
5. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
6. Outsourcing Facilities Association. Quality Analysis of Compounded Tirzepatide Products. 2024.
7. U.S. Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. 2023.
8. Eli Lilly and Company. Manufacturing and Supply Chain Overview. Investor Presentation. 2025.
9. Catalent Pharma Solutions. Press Release: Agreement with Eli Lilly for Tirzepatide Fill-Finish Services. June 2024.
10. U.S. Pharmacopeia. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2024.
11. Davies MJ et al. Gastrointestinal Effects of Tirzepatide: Gastric Emptying and Motility Analysis. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.